33rd week of 2021 patent applcation highlights part 8 |
Patent application number | Title | Published |
20210251833 | Transfer Assist Pivot Board - A transfer assist board apparatus to facilitate the transfer of a physically challenged person from one location to another has a foot plate rotably connected to a base plate. The perimeter shape of the apparatus is non-circular and has an indentation to provide a space for a care giver to place a foot to step close to the person to assist the transfer. The base plate provides a stop feature to constrain the rotation of the foot plate. | 2021-08-19 |
20210251834 | METHODS OF PREPARING A SUBJECT FOR ROTATION AND ROTATING A SUBJECT USING AN OVERHEAD LIFT - A method of rotating a subject includes arranging a lifting aid underneath the subject such that a midline of the subject is off center from a centerline of the lifting aid in a direction opposite of the rotation direction. The lifting aid includes a first loop extending in the rotation direction and a second loop extending in the opposite direction. The method further includes connecting the loops to a sling bar coupled to an overhead lift and directing the overhead lift to raise, where the subject rotates towards the direction of rotation due to the off center location of the subject. The method further includes repositioning the subject when the subject has rotated to a lateral recumbent position and directing the overhead lift to lower, thereby causing the subject to continue rotating. | 2021-08-19 |
20210251835 | RELOCATION MODULES AND METHODS FOR SURGICAL FIELD - Examples of a module for housing unrelated electronic and electromechanical equipment for use during surgery. The module can include a lower section and a tower-like upper section. The lower section can house unrelated electronic and electromechanical equipment. The tower-like upper section can be located on top of the lower section. A water-resistant cowling can enclose at least a portion of the lower section and the tower-like upper section. A cartridge containing one or more ultraviolet-C producing lights can be protectively housed within the tower-like upper section. The cartridge containing one or more ultraviolet-C producing lights can be configured to emerge upward from a top of the tower-like upper section to substantially seat itself on the top of the tower-like upper section when activated allowing the ultraviolet-C light to disinfect the patient and staff-contacting upper surfaces of the equipment in the operating room. | 2021-08-19 |
20210251836 | ANTERIOR CERVICAL POSITIONING SYSTEM - A patient positioning system for positioning a patient in preparation for an anterior cervical spinal procedure includes a base section, an upper body support attachable to a superior portion of the base section and a lower body support attachable to an inferior portion of the base section. The upper body support is configured to support the head and upper torso of the patient in a manner that aids in opening cervical spine disk space. The lower body support is configured to comfortably lift and support the legs of the patient. A traction strap assembly is attachable to the base section and configured to extend from the base section up around the shoulders of the patient and along the anterior side of the patient to a lower terminal end to enable intermittent traction of the patient's shoulders. | 2021-08-19 |
20210251837 | POSITIONING APPARATUS OF A PATIENT'S LIMB - A patient limb positioning apparatus comprises a movement assembly operating on a coupling bracket which can be engaged with the patient's limb, to move the limb according to a plurality of axes of movement. The movement assembly comprises, for at least one of said axes of movement, a drive unit which can be activated to move the coupling bracket according to a predetermined direction of movement. A load transducer detects a load transmitted between the coupling bracket and the drive unit in the respective direction of movement, to emit a signal representative of a detected load value. An electronic control unit is selectively switchable to a load control command mode and is suitable to cyclically compare the measured load value with a pre-set load value, to control activation of the drive unit when the detected load value differs from the pre-set load value. | 2021-08-19 |
20210251838 | BIO-INSPIRED ADAPTIVE IMPEDANCE BASED CONTROLLER FOR HUMAN-ROBOT INTERACTION AND METHOD - The method for controlling a single- or multi-powered robotic system, such as an exoskeleton, a prosthesis or a collaborative robot, that is physically interacting with a user, said system comprising at least one actuated joint; wherein the robot joint(s) is/are controlled in force by a low level controller using an impedance control; wherein the joint(s) output force(s) is/are determined by a high level controller using a finite state control; and wherein the high level controller finite state control is governed by a voluntary motion from the user reaching a predetermined trigger. | 2021-08-19 |
20210251839 | VARIABLE COMPRESSION BODY ANCHOR - In some embodiments, a body anchor for supporting an assistive device can include: a cuff to exert a compression force on a body part of a user; and one or more tensile elements having first ends and second ends. The first ends of the tensile elements can be configured to be attached to the assistive device. The second ends of the tensile elements can be arranged about the cuff to cause the compression force to vary in proportion to a load exerted by the assistive device. | 2021-08-19 |
20210251840 | ADAPTED FITNESS EQUIPMENT - An exercise apparatus includes an adjustable frame being attachable to an assistive ambulation device. The adjustable frame includes removable handles, fitting arms located on a lower portion of the adjustable frame to receive a fitness attachment, and attachment points on located on the lower portion of the adjustable frame to couple a resistance device. A jump rope trainer includes a handle; flexible tubing including a handle fastener to connect the handle to the flexible tubing; and a soft sphere shaped object. The flexible tubing includes a soft sphere shaped object fastener to connect the soft sphere shaped object to the flexible tubing. | 2021-08-19 |
20210251841 | SYSTEMS, METHODS AND APPARATUS FOR DIFFERENTIAL AIR PRESSURE DEVICES - Described herein are various embodiments of differential air pressure systems and components for differential air pressure systems. The air pressure systems comprise a chamber for receiving at least a portion of a user's body. Pressure in the chamber can be changed to adjust force on the user's body. Described herein are various methods and related structures for sealing a user into a pressurizable chamber. Also described herein are various methods and related structures for changing the shape and/or height of the chamber. Described herein are various types and configurations of chambers and support structures for chambers. Also described herein are various methods and related systems for treating various conditions using the differential air pressure systems, including but not limited to obesity, cardiac disease, multiple sclerosis, cerebral palsy, or Down Syndrome. | 2021-08-19 |
20210251842 | COMPRESSION APPARATUS AND SYSTEMS FOR CIRCULATORY-RELATED DISORDERS - A garment for providing circulatory-related disorder therapy includes a skin contacting layer, a backing layer, and a coupling. The backing layer is coupled to the skin contacting layer such that the skin contacting layer and the backing layer form a plurality of macro-chambers. A first one of the plurality of macro-chambers is partitioned into a plurality of micro-chambers. Each of the plurality of micro-chambers is in direct fluid communication with at least one other of the plurality of micro-chambers. The coupling is coupled to the backing layer and is configured to supply pressurized air directly into the first macro-chamber such that the pressurized air is delivered to a first one of the plurality of micro-chambers of the first macro-chamber. | 2021-08-19 |
20210251844 | VIBRATING THERAPEUTIC APPAREL - A therapeutic apparel article is configured with a supple wearable fabric article that can be configured over limb or nub of an amputated limb. The therapeutic apparel article is configured with a plurality of nodes for detachably attaching vibrating devices thereto. In addition, a control unit having a power source may be detachably attached to the wearable fabric article. A conductive network may extend from the control unit and/or the power source to provide electrical power to the nodes and the vibrating devices attached. A user may attach vibrating devices to various nodes of the wearable fabric article as desired. In addition, the vibrating devices and the control unit can be detached from the wearable fabric article to enable the wearable fabric article to be washed. | 2021-08-19 |
20210251845 | APPLYING PREDETERMINED SOUND TO PROVIDE THERAPY - A system, method and device for providing sound-based therapies to a user. The system, method, and device employ an initial measurement about a user (either or both distances on said user's head or recorded sound), a determination of a resonant frequency, and a wearable actuator affixed on said user's person with the ability to provide a unique resonant frequency to the user. The aspects disclosed herein may also incorporate microphones to optimize and monitor the treatment. | 2021-08-19 |
20210251846 | BLOOD FLOW IMPROVEMENT DEVICE, CHAIR, BED - A setting unit sets a sound stimulus for improving blood flow. A sound generator generates the set sound stimulus. The setting unit sets a sound stimulus of a sound volume level of 65 decibels or more and a frequency of a value from 5 to 250 hertz. The sound generator may generate a sound stimulus of a continuous sound or generate a sound stimulus in an intermittent pattern in which an output period of the sound stimulus and a non-output period of the sound stimulus are alternately repeated. The setting unit may determine the sound volume level generated from the sound generator according to the distance to a subject. | 2021-08-19 |
20210251847 | Magnetic Spa Jet - A magnetic spa jet is provided. The device includes a housing having a base and a perimeter sidewall defining an interior volume. A first magnetic member is affixed to a shaft, wherein the shalt extends through an opening disposed in the base such that the first magnetic member is disposed within the interior volume. An impeller includes a second magnetic member on a lower side thereof, wherein the second magnetic member is magnetically attracted to the first magnetic member. Upon rotation of the first magnetic member about the shaft, the second magnetic member rotates the impeller in kind. A cap is removably securable to the housing about the perimeter sidewall, wherein the cap includes a plurality of apertures therethrough. | 2021-08-19 |
20210251848 | TREATMENT OF BLEEDING BY NON-INVASIVE STIMULATION - Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear. | 2021-08-19 |
20210251849 | SYRINGE ASSEMBLY AND ADAPTER MEMBER - A syringe assembly ( | 2021-08-19 |
20210251850 | SYSTEM AND METHODS FOR TREATING CANCER CELLS WITH ALTERNATING POLARITY MAGNETIC FIELDS - Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to a target body area that includes the cancer or other rapidly-dividing cells. | 2021-08-19 |
20210251851 | ETHER/ESTER COMPOSITE POLYURETHANE FOAM COSMETIC - The present invention relates to a cosmetic comprising polyurethane foam in which a liquid cosmetic substance is impregnated. The present invention provides a cosmetic comprising polyurethane foam in which a cosmetic composition is impregnated, wherein the polyurethane of the polyurethane foam comprises an ether group and an ester group in a molar ratio of 4:6 to 6:4, the −2021-08-19 | |
20210251852 | Aloe Mint Scalp Wipes - This present invention relates to scalp nourishing wipes used to prevent dry scalp and to remove any dirt buildup or fungus development that causes itchy scalps. The scalp wipes are infused with a novel aloe and mint based solution. The scalp wipes can be applied to the scalp surface to maintain the moisture level of the skin, which eventually nourishes the skin in single application. The scalp wipes are manufactured using bio-degradable material and is eco-friendly. Further, the scalp wipes of the present invention can be stored in containers that features a sealed lid to prevent the scalp wipes from prematurely drying out. | 2021-08-19 |
20210251853 | Tooth-Attachable Patch Capable of Being Removed by Tooth Brushing - The present invention provides a patch for attaching to teeth or a surrounding part of teeth, and the patch can be easily removed by tooth brushing alone. | 2021-08-19 |
20210251854 | OIL-IN-WATER TYPE SOLID COSMETIC MATERIAL AND COSMETIC PRODUCT - The oil-in-water type solid cosmetic material contains a powder component, a gelling agent, a water-soluble thickener, water, and an oiling agent, wherein a plate-like powder, which has an average particle size of 10 to 200 μm and has an aspect ratio of 40 to 200, is contained, as the powder component, in an amount of 3% to 30% by mass based on a total amount of the cosmetic material; and agar and/or gellan gum is contained as the gelling agent. | 2021-08-19 |
20210251855 | TWO-STEP REACTIVE LIP SYSTEM - Disclosed is a two-step cosmetic product, such as used on the lips, where the basecoat includes a surface-stabilized dispersion of copolymer particles and a styrenic block copolymer, and the topcoat includes a silicone amine. | 2021-08-19 |
20210251856 | COMPOSITION COMPRISING A SATURATED FATTY ALCOHOL, AT LEAST ONE FATTY-CHAIN ANIONIC SURFACTANT, A POLYOL AND AT LEAST ONE SILICONE OIL - Composition comprising a saturated fatty alcohol, at least one fatty-chain anionic surfactant, a polyol and at least one silicone oil The present invention relates to a composition, preferably a cosmetic composition, in the form of an oil-in-water emulsion, in which an oily phase is dispersed in an aqueous phase, comprising: (a) from 2.5% to 7% by weight, relative to the total weight of the composition, of at least one saturated C16-C22 and preferably C16-C18 fatty alcohol; (b) at least one anionic surfactant including at least one C16-C22 and preferably C16-C18 hydrocarbon-based chain; (c) at least one polyol; (d) at least 60% by weight, relative to the total weight of the oily phase, of at least one silicone oil; the fatty alcohols (a)/anionic surfactants (b) mass ratio being between 10:1 and 6:4. The composition according to the invention has the advantage of having a very soft, non-tacky texture which is fresh on application, and is thus very pleasant touse and easy to apply. Moreover, the composition is stable, and is notably macroscopically and microscopically stable after two months of storage under temperature conditions ranging from 4° C. to 45° C. | 2021-08-19 |
20210251857 | PERSONAL CLEANSING COMPOSITION - A personal cleansing comprising, in an aqueous continuous phase: a total amount of anionic surfactant, amphoteric surfactant and zwitterionic surfactant consisting of: (i) from 3 wt % to less than 7 wt %, by weight of the total composition at 100% activity, of an alkyl ether sulfate anionic surfactant of general formula (I): R—O—(CH | 2021-08-19 |
20210251858 | METHOD FOR MAKING TOOTHPASTE ENABLING ENAMEL RESTORATION - A method for making a toothpaste enabling enamel restoration proposes to encapsulate soluble calcium and phosphate salts within corresponding internal water phases in respective water-in-oil-in-water emulsions. In this way, the soluble calcium and phosphate salts can be present stably in the toothpaste over a long period of time without causing precipitation of calcium phosphate. When the toothpaste of the present disclosure is used in brushing teeth, the water-in-oil-in-water emulsions are ruptured under the effect of friction and pressing, releasing the soluble calcium and/or phosphate salts encapsulated within the corresponding internal water phases. As a result, the liquid in the user's oral cavity will contain high concentrations of calcium and phosphate ions, which can enhance the rate of remineralization of enamel and/or dentin exposed to the oral cavity. | 2021-08-19 |
20210251859 | METHOD FOR MAKING COMPOSITION FOR ENAMEL REGENERATION - A method for making a composition for enamel regeneration proposes to encapsulate soluble calcium and phosphate salts within corresponding internal water phases in respective water-in-oil-in-water emulsions stabilized by solid particles, and add them to a toothpaste, enamel restoring gel or mouth wash base. In this way, the soluble calcium and phosphate salts can be present stably in the toothpaste, enamel restoring gel or mouth wash over a long period of time. When the toothpaste, enamel restoring gel or mouth wash of the present disclosure is used in oral cavity, the water-in-oil-in-water emulsions rapture under the effect of friction and pressing, releasing the soluble calcium and phosphate salts encapsulated within the corresponding internal water phases. As a result, the liquid in the user's oral cavity will contain high concentrations of calcium and phosphate ions, which can enhance the rate of enamel remineralization. | 2021-08-19 |
20210251860 | POLYHYDROXY FULLERENE SUNSCREEN ACTIVE AGENTS AND COMPOSITIONS - Sunscreen compositions comprising a dermatologically acceptable carrier and a polyhydroxy fullerene compound are described. The sunscreen compositions can be used to protect a substrate such as the skin of a subject from the effects of ultraviolet radiation. | 2021-08-19 |
20210251861 | METHOD FOR TOPICAL PROTECTION AGAINST ATMOSPHERIC POLLUTANT MOLECULES AND/OR FREE RADICALS PRODUCED BY EXPOSURE TO ULTRAVIOLET RADIATION - A method of providing topical protection against atmospheric pollutant molecules and against ultraviolet (UV) radiation, said method comprising the steps of:
| 2021-08-19 |
20210251862 | Prebiotic Oral Care Compositions Containing Carboxylic Acids - The present invention provides an oral care composition comprising a carboxylic acid of the formula: | 2021-08-19 |
20210251863 | PRESERVATION COMPOSITIONS - An antimicrobial preservation system comprising: i. itaconic acid or salt thereof and ii. benzoic acid or salt thereof. | 2021-08-19 |
20210251864 | ECO EMULSIFIER | 2021-08-19 |
20210251865 | HYBRID QUATS IN, IN PARTICULAR, HAIR TREATMENT AGENTS - The invention relates to compositions comprising
| 2021-08-19 |
20210251866 | SODIUM LAUROYL SARCOSINATE CONTAINING DETERGENT COMPOSITIONS - A detergent composition and a method of washing/cleaning urushiol at least partially, more typically substantially or completely off a surface of human skin or clothing. The detergent composition is typically a non-buffered composition that contains one or more C12 surfactants, typically at least a sodium lauroyl sarcosinate and the detergent composition is typically free of one or more of (1) any nonylphenol ethoxylate; (2) any pharmaceutically active drug or prodrug; (3) any salt in an amount that affects the functional characteristics of either of the solely C12 surfactants; (4) any salt in granular form; and/or (5) any ethoxylate that is a stand-alone ingredient. | 2021-08-19 |
20210251867 | FOAMING COMPOSITION - The present invention relates to a composition comprising: (a) at least one ether oil; (b) at least one amphoteric surfactant chosen from (C | 2021-08-19 |
20210251868 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE ALKYL OR ALKYLENE CARBONATE - The present invention relates to a notably cosmetic or dermatological composition comprising: a) at least one merocyanine of formula (1) or (2) and (2) b) at least one oily phase comprising at least one alkyl or alkylene carbonate. The present invention also relates to a non-therapeutic cosmetic process for caring for and/or making up a keratin material, comprising the application, to the surface of said keratin material, of at least one composition as defined hereinabove. The invention also relates to a non-therapeutic cosmetic process for limiting the darkening of the skin and/or improving the colour and/or uniformity of the complexion, comprising the application, to the surface of the keratin material, of at least one composition as defined previously. The invention also relates to a non-therapeutic cosmetic process for preventing and/or treating the signs of ageing of a keratin material, comprising the application, to the surface of the keratin material, of at least one composition as defined previously. | 2021-08-19 |
20210251869 | SKIN TREATMENT METHODS - The invention provides a compound of formula (I) | 2021-08-19 |
20210251870 | ORAL CARE COMPOSITION - An oral care composition including greater than 0.0% of an antimicrobial agent that is cetylpyridinium chloride (CPC), a cationic surfactant, an emulsifier, and less than 0.5% by weight of a thickener, such as hydroxyethylcellulose. | 2021-08-19 |
20210251871 | SUN CARE COMPOSITION FOR WHITENING THE SKIN, USE OF THE SUN CARE COMPOSITION, AND PROCESS OF MANUFACTURE OF THE SUN CARE COMPOSITION - The present invention relates to a cosmetic composition to be used on the skin comprising the combination of a particular whitening system, a UVA filter system, and a combination of antioxidants for effectively whitening the skin, in particular the skin of the face, while also protecting these materials from the damages caused by UVA radiation. | 2021-08-19 |
20210251872 | FUSION PROTEIN BOUND TO CELL-PERMEABLE PEPTIDE, ANDCOMPOSITION COMPRISING FUSION PROTEIN OR CELL-PERMEABLEPEPTIDE AND EPITHELIAL CELL GROWTH FACTOR AS ACTIVEINGREDIENTS - The present invention pertains to: a botulinum toxin, epithelial cell growth factor, or hexapeptide fusion protein bound to skin tissues and cell-permeable peptides, or an epithelial cell growth factor mixed with skin tissues and cell-permeable peptides; and a composition comprising same. The fusion protein or the epithelial cell growth factor mixed with cell-permeable peptides has increased cell permeability compared to protein by itself, and is thus useful for improving the condition of skin, treating wrinkles, relieving muscle tension, and treating wounds. | 2021-08-19 |
20210251873 | DETERGENT COMPOSITIONS FOR WASHING URUSHIOL AND METHODS OF TREATING URUSHIOL INDUCED CONTACT DERMATITIS - A composition and a method of washing urushiol off the surface of human skin. The composition includes a first solely C12 surfactant and a second solely C12 surfactant that are each in a non-buffered composition and the composition is free of each of the following: (1) any nonylphenol ethoxylate, (2) any pharmaceutically active drug or prodrug, or (3) any salt that affects the functional characteristics of either of the solely C12 surfactants. | 2021-08-19 |
20210251874 | COMPOSITION WITH LONG-LASTING CONCEALING EFFECTS - The present invention relates to a composition comprising: (a) at least one pigment; (b) at least one first copolymer of at least two monomers selected from (meth)acrylic acid, esters thereof, and salts thereof; (c) at least one second copolymer of styrene or α-methylstyrene and of at least one monomer selected from (meth)acrylic acid, esters thereof, and salts thereof, wherein the weight ratio of the amount of the (c) second copolymer(s)/the amount of the (a) pigment(s) is 1.0 or more, preferably 1.5 or more, and more preferably 2.0 or more, and the composition comprises at least one non-ionic surfactant in an amount of 0.5% by weight or less, preferably 0.3% by weight or less, and more preferably 0.1% by weight or less, relative to the total weight of the composition, or the composition comprises no non-ionic surfactant. The composition according to the present invention is suitable for a keratin substance such as the skin and the surface of a mucous membrane, and can provide the keratin substance with enhanced or improved cosmetic effects, such as better concealing effects of the original color of the keratin substance, as well as long-lasting makeup effects. | 2021-08-19 |
20210251875 | COSMETICS - A cosmetic material containing a component (A): ionic polymer particles containing structural units derived from (a) one or more hydrophobic monomers selected from the group consisting of styrene and a derivative thereof, a vinyl ester, and a hydrophobic acrylic monomer, and (b) an ionic hydrophilic monomer or a salt thereof, wherein the ratio by mass of (a) to (b), (a)/(b) is 99.5/0.5 to 80/20, and the tetrahydrofuran-insoluble fraction therein is 10% or more and 100% or less, and a component (B): UV protective agent, wherein the ratio by mass of the component (A) to the component (B) is 5/95 to 30/70. | 2021-08-19 |
20210251876 | UV PROTECTION COSMETIC COMPOSITION - A UV protection cosmetic composition is provided. The composition may include an organic UV protection agent, a thickening agent, a silicone elastomer, ethanol and oil. | 2021-08-19 |
20210251877 | TWO-STEP REACTIVE LIP SYSTEM - Disclosed is a two-step cosmetic product, such as used on the lips, where the basecoat includes a surface-stabilized dispersion of copolymer particles, and the topcoat comprises a silicone amine and a viscous silicone, the viscous silicone having a viscosity of at least about 100,000 centistoke when measured at a concentration by weight of 100% and using a rotational viscometer at 25° C. | 2021-08-19 |
20210251878 | DETERGENT - The present invention relates to a detergent containing or prepared by blending: (A) an anionic surfactant; (B) an aminopolyether-modified silicone containing a polyoxyalkylene structure and satisfying the following formula (I); and (C) a cationic polymer, wherein a mass ratio [(A)/(B)] of the component (A) to the component (B) is 25 or more and 5,000 or less, and a mass ratio [(B)/(C)] of the component (B) to the component (C) is 0.001 or more and less than 1: | 2021-08-19 |
20210251879 | BLOCK COPOLYMERS FOR TOOTH ENAMEL PROTECTION - Described herein are block copolymers having hydrophobic blocks and hydrophilic blocks which are effective in binding to the surface of hard tissue; compositions comprising the same, as well as methods of making and using the same. | 2021-08-19 |
20210251880 | MINERAL BASED COMPOSITIONS AND USE THEREOF - Mineral-based composition and methods of use thereof in preventing skin damages, such as in subjects exposed to radiation, are provided. | 2021-08-19 |
20210251881 | COMPOSITIONS COMPRISING KAKADU PLUM EXTRACT OR ACAI BERRY EXTRACT - A method of lightening skin or reducing internal or external oxidation of a cell of skin is disclosed. The method can include topically applying to the skin a composition consisting of | 2021-08-19 |
20210251882 | TOPICAL COSMETIC COMPOSITIONS - The present invention relates generally to methods and compositions useful for a topical composition comprising escin, lecithin, plankton extract, | 2021-08-19 |
20210251883 | METHOD FOR PREPARING ENZYME-TREATED ZIZANIA LATIFOLIA TURCZ. EXTRACT HAVING INCREASED TRICIN CONTENT, AND COMPOSITION FOR WHITENING, WRINKLE REDUCTION, ANTI-INFLAMMATION, ANTI-ALLERGY AND MOISTURIZATION, PREPARED THEREBY - The present invention relates to a method of preparing an enzyme-treated | 2021-08-19 |
20210251884 | Anti-Obesity Agent, Anti-Dementia Agent, Deodorant, Anti-Aging Agent, Anti-Glycation Agent, Anti-Type I Allergy Agent, Hypotensive Agent, Flavor Improving Agent, Muscle Enhancing Agent, and Bone Metabolism Improving Agent - One aspect of the present invention provides an anti-obesity agent, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, a hypotensive agent, a flavor improving agent, a muscle enhancing agent, and a bone metabolism improving agent which contain a bagasse decomposition extract as an active ingredient. | 2021-08-19 |
20210251885 | COSMETIC PREPARATION AGAINST ACNE - Cosmetic product of a packaging means having two spatially separated chambers, wherein the first chamber contains a lyophilisate of bacteria of the strains | 2021-08-19 |
20210251886 | ORAL MUCOSAL DELIVERY SYSTEMS COMPRISING MONOPHASIC CONCENTRATE OF TERIPARATIDE - This invention comprises a water free liquid composition comprising Teriparatide for transmucosal delivery that adheres to mucosa after coming in contact with mucosal surface and a system of making dosage form from the same and delivering to mucous membrane at various locations though liquid drops, capsule or tablets. The liquid composition is characterized by being a monophasic composition. The liquid monophasic composition comprises a non-aqueous liquid as carrier, a penetration enhancer/permeation enhancer, stabilizer and a surfactant. The liquid composition of Teriparatide intended to be dispensed to a mucosal membrane of oral/buccal cavity as liquid drops, or of oral/buccal cavity or nasal cavity as an oral or nasal spray or of oral/buccal cavity as an oral film; or of a part of alimentary canal as incorporated in a capsule or a tablet as an ingredient. | 2021-08-19 |
20210251887 | INJECTABLE FORMULATIONS FOR TREATING CANCER - The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders. | 2021-08-19 |
20210251888 | READY TO USE LIQUID FORMULATION - Disclosed herein is a ready-to-use liquid, injectable formulation comprising lidocaine and epinephrine. Also disclosed herein is a process for preparing a ready-to-use liquid formulation comprising lidocaine and epinephrine, as well as methods for using the ready-to-use liquid formulation. | 2021-08-19 |
20210251889 | N-Acetylcysteine Compositions and Methods - Storage stable sterile ready-to-administer formulations comprising N-acetylcysteine are presented with desirable stability characteristics. In preferred aspects, formulations comprise low quantities of one or more chelating agents, contain N-acetylcysteine at a concentration of 25 mg/mL or 50 mg/mL, and are packaged in a suitable format, such as a polymeric bag with a metalized overwrap and a non-contact oxygen scavenger. | 2021-08-19 |
20210251890 | HEMOSTATIC COMPOSITIONS AND RELATED METHODS - Compositions and related kits and methods for treating a target site of a patient are described herein. The composition may include a hemostatic agent and a pH agent, for example. Methods of treatment include delivering and applying the hemostatic agent and the pH agent to a gastrointestinal system of a patient via a medical device to reduce bleeding of tissue in the gastrointestinal system. | 2021-08-19 |
20210251891 | CHLOROGENIC ACID-CONTAINING COMPOSITION FOR NASAL ADMINISTRATION - An anti-tumor composition for nasal administration has chlorogenic acid as an active ingredient, with the addition of pharmaceutically acceptable excipients or auxiliary ingredients. The chlorogenic acid preparation can improve the bioavailability of chlorogenic acid for nasal administration, penetrate the blood-brain barrier, have a significant inhibitory effect on brain tumors and nasopharyngeal carcinoma, and possess a clinical application value. | 2021-08-19 |
20210251892 | IMPLANTABLE DEVICE FOR DELIVERY OF THERAPEUTIC SUBSTANCES TO THE EYE - Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device. | 2021-08-19 |
20210251893 | Compositions and Methods for Treating Ocular Diseases - The present invention relates to the treatment of ocular diseases in a human subject. In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant. | 2021-08-19 |
20210251894 | FUNCTIONAL BEVERAGE COMPOSITIONS AND METHODS OF USING AND MAKING SAME - Functional beverage compositions in liquid form. The functional beverage compositions include water, lecithin, a punicic acid-containing oil, and a cannabinoid-containing oil. The punicic acid-containing oil and the cannabinoid-containing oil are stably suspended within the water. Methods of using the compositions include administering the compositions to reduce inflammation in a subject or treat an inflammation-related disease in a subject. Methods of making the compositions include suspending the punicic acid-containing oil and the cannabinoid-containing oil in a sub-volume of water and adding additional water to arrive at a final composition volume. | 2021-08-19 |
20210251895 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS - The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human, a method for using creatinine to improve the bioavailability of creatine, and a metn. | 2021-08-19 |
20210251896 | PARACETAMOL LIQUID SUSPENSIONS - Pharmaceutical liquid suspensions containing paracetamol wherein the suspensions are formulated with paracetamol particles having a d50 of less than or equal to 10 μm and a d90 of less than or equal to 35 μm such that browning discoloration is reduced during prolonged storage. | 2021-08-19 |
20210251897 | NANOPARTICLE ARSENIC-PLATINUM COMPOSITIONS - The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer. | 2021-08-19 |
20210251898 | LIPID NANOPARTICLE MRNA VACCINES - The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination. | 2021-08-19 |
20210251899 | POLYMERSOMES COMPRISING A SOLUBLE ENCAPSULATED ANTIGEN AS WELL AS METHODS OF MAKING AND USES THEREOF - The present invention relates to polymersomes comprising a soluble encapsulated antigen, wherein said soluble encapsulated antigen is selected from the group consisting of: a polypeptide, a carbohydrate, a polynucleotide and combinations thereof. The present invention further relates to a method for production of encapsulated antigens in a polymersome as well as to polymersomes produced by said method. The present invention further relates to compositions comprising a polymersome of the present invention, isolated antigen presenting cells or hybridoma cells exposed to the polymersome or composition of the present invention. The present invention also relates to vaccines comprising polymersomes of the present invention, methods of eliciting an immune response or methods for treatment, amelioration, prophylaxis or diagnostics of a cancer, autoimmune or infectious disease, comprising providing polymersomes of the present invention. | 2021-08-19 |
20210251900 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY - The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula I, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm: | 2021-08-19 |
20210251901 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same - Fine dry particulate adenosine compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate adenosine composition, the adenosine active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate adenosine compositions of the invention, and methods of using the same. | 2021-08-19 |
20210251902 | DELAMANID-CONTAINING COMPOSITION - Provided is a composition comprising delamanid particles for which the formation of secondary particles is suppressed. Specifically, provided is a composition comprising (A) delamanid particles and (B) a surface stabilizer. | 2021-08-19 |
20210251903 | Preparation of Microparticulate Triamcinolone Acetonide Injectable Suspension - The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. Particularly, the invention relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization of an aqueous slurry of the steroid triamcinolone acetonide in the presence of benzyl alcohol, sodium chloride and sodium carboxymethylcellulose under a nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed. | 2021-08-19 |
20210251904 | METHOD FOR PRODUCING GRANULES CONTAINING A CORE PARTICLE, GRANULES CONTAINING A CORE PARTICLE, PHARMACEUTICAL COMPOSITION CONTAINING THE GRANULES CONTAINING THE CORE PARTICLE, AND PREPARATION CONTAINING THE PHARMACEUTICAL COMPOSITION - A method for producing granules containing a core particle by using a general granulation method is provided. Granules containing a core particle produced by the method are provided. In addition, a pharmaceutical composition and preparation containing the granules containing the core particle are provided. The granulation method according to an embodiment of the present invention granulates by splaying granulation liquid having a mist diameter (D | 2021-08-19 |
20210251905 | POLY(METH)ACRYLIC ACID POPCORN POLYMERIZATES AS DISINTEGRANTS FOR TABLETS - The use of powder-form, crosslinked, water-insoluble, low-swelling polyacrylates as disintegrants for solid pharmaceutical dosage forms. | 2021-08-19 |
20210251906 | PREGABALIN EXTENDED-RELEASE FORMULATIONS - Extended-release formulations can be prepared that comprise a core and an optional coating layer formed over the core. The core comprises a therapeutically effective amount an active pharmaceutical ingredient (API), a non-swelling matrix forming agent comprising a water-soluble agent and a water-insoluble polymer; one or more extended-release agents; an optional, wicking agent; and one or more optional excipients. Such formulations may be useful for preparing extended-release formulations of pregabalin that are suitable for once-daily dosing for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN). | 2021-08-19 |
20210251907 | Encased Tamper Resistant Controlled Release Dosage Forms - In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C. | 2021-08-19 |
20210251908 | SOLID PREPARATION COMPOSITION FOR ORAL ADMINISTRATION OF COLONIC PURGATIVE CONTAINING ANHYDROUS SODIUM SULFATE, POTASSIUM SULFATE, ANHYDROUS MAGNESIUM SULFATE AND SIMETHICONE - The present invention relates to a solid colonic purgative for oral application, containing anhydrous magnesium sulfate, potassium sulfate, anhydrous sodium sulfate, and, additionally, simethicone. The present invention is more satisfactory in the colon cleansing effect even with the doses reduced by up to about 20 percent compared to those of a conventional colonic purgative consisting of anhydrous magnesium sulfate, potassium sulfate and anhydrous sodium sulfate. Besides, the present invention, due to the reduced doses, has less unpleasant taste or odor caused by the main ingredients and requires a less intake of the preparation and water, improving drug compliance significantly. Further, unlike the conventional solid colonic purgative, the present invention can be prepared into tablets without using a water-soluble lubricant. In other words, the present invention can be formulated into a solid preparation for oral application by using a water-soluble lubricant, or even without using any water-soluble lubricant. | 2021-08-19 |
20210251909 | TASTE MASKING DRUG FORMULATIONS - The present disclosure relates to a taste-masking microcapsule composition The composition comprises a core portion encapsulated by a shell portion. The core portion comprises an active pharmaceutical ingredient (API) and one or more excipients. The shell portion comprises a hydrophobic matrix and a pH-responsive material. The microcapsule compositions prevent API release at the more neutral pH levels in the oral cavity, but upon exposure to pH levels of the stomach, the pH-responsive material becomes soluble thereby permitting release of the API. | 2021-08-19 |
20210251910 | FUMARIC ACID COMPOSITIONS WITH INCREASED BIOAVAILABILITY AND REDUCED SIDE EFFECTS - Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of a nonsteroidal anti-inflammatory drug (NSAID), such as aspirin, and a second amount of fumaric acid or an ester or a salt thereof. The NSAID is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 to about 420 mg per day. The compositions are formulated so that, upon oral administration to a subject, the both the NSAID and the fumaric acid or ester or salt thereof are released in the gastrointestinal track of the subject, and the NSAID is released at substantially the same time as, slower than, or later than the fumaric acid or ester or salt thereof. The delayed release of NSAID, it is herein observed, increased the bioavailability of the fumaric acid or ester or salt thereof. | 2021-08-19 |
20210251911 | Nanoparticles Containing a Taxane and their Use - Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclitaxel and derivatives thereof, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy. | 2021-08-19 |
20210251912 | Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and 9-Tetrahydrocannabinol (THC) - A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and Δ | 2021-08-19 |
20210251913 | PATCH - The patch of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, wherein a water vapor transmission rate of the backing layer is 400 g/m | 2021-08-19 |
20210251914 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE - The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine. | 2021-08-19 |
20210251915 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE - The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine. | 2021-08-19 |
20210251916 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING RIVASTIGMINE - The present invention relates to a transdermal therapeutic system for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; B) a rivastigmine-containing layer comprising at least one acrylic polymer; and C) a skin contact layer comprising at least one styrene-isoprene-styrene block copolymer and at least one tackifier. | 2021-08-19 |
20210251917 | COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE AND MAKING THEREOF - Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of CBD to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability. | 2021-08-19 |
20210251918 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING SEIZURE DISORDERS - The present disclosure relates to the transdermal administration of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). | 2021-08-19 |
20210251919 | METHODS OF ADMINISTERING AMANTADINE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2021-08-19 |
20210251920 | PUTRESCINE TOPICAL BARRIER FORMULATION - The present invention describes stable topical barrier compositions comprising primary polyamines and uses thereof for protecting the skin from external stressors, for improving skin's moisture and fort stimulating healing of the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and inflammation, for increasing skin's moisture and/or for reducing or preventing skin's signs of aging. | 2021-08-19 |
20210251921 | USE OF RASAGILINE FOR THE TREATMENT OF RESTLESS LEGS SYNDROME - Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically accepable salt thereof. | 2021-08-19 |
20210251922 | Methods and Compositions for the Treatment of Steatosis-Associated Disorders - The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. | 2021-08-19 |
20210251923 | METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS - In various aspects and embodiments provided are compositions and methods for improving cognition and/or treating a neurodegenerative disease in a patient. In some embodiments the compositions and methods include identifying a patient in need of, or desiring improvement of, cognitive function and/or treatment of a neurodegenerative disease and administering to the patient a β agonist and optionally a peripherally acting β-blocker (PABRA). | 2021-08-19 |
20210251924 | OXPRENOLOL COMPOSITIONS FOR TREATING CANCER - The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients. | 2021-08-19 |
20210251925 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF - Compounds and compositions including stereoisomers of 6-phenylhexanamide derivative small molecule mitofusin activators are described. In particular, mitofusin activators comprising derivatives of (trans-4-hydroxycyclohexyl)-6-phenylhexanamide, which are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin-1 (MFN1) and/or mitofusin-2 (MFN2), or mitochondrial dysfunction, are described. Methods of treatment and pharmaceutical formulations are also described. | 2021-08-19 |
20210251926 | TOPICAL COMPOSITION AND DELIVERY SYSTEM AND ITS USE - The described invention provides a topical delivery system comprising a pharmaceutical composition for application directly to a skin of a subject in need thereof comprising (a) an effective therapeutic amount of an active therapeutic agent; (b) chemical drivers comprising an amino benzoate local anesthetic, ethoxydiglycol and methylsulfonylmethane (MSM) that in combination are effective to synergistically deliver the therapeutic agent; and (c) a depot component for keeping the pharmaceutical composition in the skin. Methods for delivering an active therapeutic agent into skin, for keeping it in the skin, for reducing systemic side effects attributable to entry of the active agent into the blood stream, and a method for treating a condition, disease or disorder of skin topically also are described in accordance with the embodiments of the described invention. | 2021-08-19 |
20210251927 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF - Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described. | 2021-08-19 |
20210251928 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS - A method of treating tinnitus in a subject is described that includes administering a therapeutically effective amount of a group II metabotropic glutamate receptor (mGluR) agonist to the subject. A method of screening a subject having tinnitus for treatment with a group II mGluR agonist that includes testing the use of residual inhibition to suppress tinnitus in the subject, wherein suppression of tinnitus by residual inhibition indicates that a group II mGluR agonist would be effective for treating tinnitus in the subject, is also described. | 2021-08-19 |
20210251929 | ANTI-RDS COMPOUNDS AND METHOD OF MANUFACTURE AND ADMINISTRATION THEREOF TO INDUCE DOPAMINE HOMEOSTASIS - Compounds for treating reward deficiency syndrome (RDS) behaviors and methods of use and administration of such compounds to induce dopamine homeostasis are disclosed. These compounds synergistically combine two or more of (a) DPA, (b) NAC, and (c) kyotorphin (or arginine and tyrosine, the precursors of kyotorphin). These work together to enhance dopamine release by employing mechanisms tied to GABA regulation on Dorsal Raphe VGlut3 neurons via the Substania Nigra and increasing enkephalins (by increasing the release of enkepahlins and by the inhibition of enkephalinase). The resulting compound can induce dopamine homeostasis (and thus induce anti-stress states and diminish stress induced addictive behaviors). In some embodiments, the compound further includes nano-sized particles that enable the compound to be water- or powder-based even though DPA, NAC, and kyotorphin are not soluble in water. | 2021-08-19 |
20210251930 | HIV INHIBITORS - The present invention relates to a compound comprising of the nucleotide sequence UAA or TAA and a binding site for the covalent attachment of leucine (Leu), wherein said compound is recognized by a ribosome, for use in medicine. | 2021-08-19 |
20210251931 | LEVOTHYROXINE LIQUID FORMULATIONS - The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes a cyclodextrin and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use. | 2021-08-19 |
20210251932 | Method Of Treatment Of Obesity - The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight. | 2021-08-19 |
20210251933 | METHODS FOR TREATING TAUOPATHY - Disclosed are uses of isotopically modified polyunsaturated compounds for treating, ameliorating or inhibiting the progression of a neurodegenerative disease or condition related to tauopathy in a subject in need thereof. In certain embodiments, the isotopically modified polyunsaturated compounds are deuterated polyunsaturated fatty acids or derivatives thereof. | 2021-08-19 |